NBRV(Delisted)
Nabriva Therapeutics·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NBRV
Nabriva Therapeutics Plc
A biopharmaceutical company that developing innovative anti-infective agents to treat serious infections
Alexandra House, Office 225/227, The Sweepstakes, Dublin 4, Ireland
--
Nabriva Therapeutics plc was founded in Austria in October 2005. On March 1, 2017, the company was incorporated in Ireland. The company is a clinical-stage biopharmaceutical company engaged in the development of new anti-infective drugs for the treatment of serious infections, mainly developing antibiotics for pleuromutilin.
Company Financials
EPS
NBRV has released its 2023 Q1 earnings. EPS was reported at -2.72, versus the expected 0, missing expectations. The chart below visualizes how NBRV has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NBRV has released its 2023 Q1 earnings report, with revenue of 7.59M, reflecting a YoY change of -5.36%, and net profit of -8.70M, showing a YoY change of 26.39%. The Sankey diagram below clearly presents NBRV's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
